Urodynamic investigation of cyclophosphamide-induced overactive bladder in conscious rats

Chinese Medical Journal

Volumn 125, Issue 2, 2012, Pages 321-325

  Pan, Feng ^a   Liu, Di ^a   Han, Xiao Min ^a   Li, Wen Cheng ^a   Pang, Zi Li ^a   Li, Bing ^a   Zhang, Xiao Ping ^a   Xiao, Ya Jun ^a   Zeng, Fu Qing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cyclophosphamide; Overactive; Urinary bladder; Urodynamics

Indexed keywords

CYCLOPHOSPHAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER BLEEDING; BLADDER CATHETERIZATION; BLADDER COMPLIANCE; BLADDER MUCOSA; BLADDER PRESSURE; BLADDER WALL; CONSCIOUSNESS; CONTROLLED STUDY; CYSTITIS; CYSTOMETRY; DETRUSOR MUSCLE; DISEASE SEVERITY; FEMALE; LYMPHOCYTIC INFILTRATION; MICROSCOPY; MICTURITION; NONHUMAN; OVERACTIVE BLADDER; PATHOGENESIS; RAT; SMOOTH MUSCLE CONTRACTION; URODYNAMICS;

ANIMALS; CONSCIOUSNESS; CYCLOPHOSPHAMIDE; FEMALE; RATS; RATS, SPRAGUE-DAWLEY; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 84862950927     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.02.029     Document Type: Article

References (25)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-178.
2. Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 2003; 62: 28-37.
3. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006; 97: 96-100.
4. Wyndaele JJ. The overactive bladder. BJU Int 2001; 88: 135-140.
5. Chancellor MB. New frontiers in the treatment of overactive bladder and incontinence. Rev Urol 2002; 4: 50-56.
6. + channel 2.1 and 2.2 in rat bladder with detrusor hyperreflexia. Chin Med J 2008; 121: 1574-1577.
7. Drake MJ. The integrative physiology of the bladder. Ann R Coll Surg Engl 2007; 89: 580-585.
8. Apodaca G, Balestreire E, Birder LA. The uroepithelialassociated sensory web. Kidney Int 2007; 72: 1057-1064.
9. Sun B, Li Q, Dong L, Rong W. Ion channel and receptor mechanisms of bladder afferent nerve sensitivity. Auton Neurosci 2010; 153: 26-32.
10. Amarenco G, Leroi AM. Physiology and evaluation of overactive bladder. Neurochirurgie 2003; 49: 358-366.
11. Juszczak K, Ziomber A, Wyczolkowski M, Thor PJ. Urodynamic effects of the bladder C-fiber afferent activity modulation in chronic model of overactive bladder in rats. J Physiol Pharmacol 2009; 60: 85-91.
12. Dinis P, Charrua A, Avelino A, Cruz F. Intravesical resiniferatoxin decreases spinal c-fos expression and increases bladder volume to reflex micturition in rats with chronic inflamed urinary bladders. BJU Int 2004; 94: 153-157.
13. de Groat WC, Yoshimura N. Afferent nerve regulation of bladder function in health and disease. Handb Exp Pharmacol 2009; 194: 91-138.
14. Silva C, Ribeiro MJ, Cruz F. The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol 2002; 168: 575-579.
15. Grunberg SM. Cyclophosphamide and etoposide for non-small cell and small cell lung cancer. Drugs 1999; 58: 11-15.
16. Tabata M, Kiura K, Okimoto N, Segawa Y, Shinkai T, Yonei T, et al. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer. Cancer Chemother Pharmacol 2007; 60: 1-6.
17. Nicolini A, Mancini P, Ferrari P, Anselmi L, Tartarelli G, Bonazzi V, et al. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother 2004; 58: 447-450.
18. Nelius T, Rinard K, Filleur S. Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature. Cancer Treat Rev 2011; 37: 444-455.
19. Tanaka M, Takamatsu Y, Anan K, Ohno S, Nishimura R, Yamamoto Y, et al. Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study. Anticancer Drugs 2010; 21: 453-458.
20. Nazif O, Teichman JM, Gebhart GF. Neural upregulation in interstitial cystitis. Urology 2007; 69: 24-33.
21. Masuda H, Ichiyanagi N, Yokoyama M, Sakai Y, Kihara K, Chancellor MB, et al. Muscarinic receptor activation in the lumbosacral spinal cord ameliorates bladder irritation in rat cystitis models. BJU Int 2009; 104: 1531-1537.
22. Ito K, Iwami A, Katsura H, Ikeda M. Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. Naunyn Schmiedebergs Arch Pharmacol 2008; 377: 483-490.
23. Goldstein RE, Westropp JL. Urodynamic testing in the diagnosis of small animal micturition disorders. Clin Tech Small Anim Pract 2005; 20: 65-72.
24. Yoshiyama M, de Groat WC. Supraspinal and spinal alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid and N-methyl-D-aspartate glutamatergic control of the micturition reflex in the urethane-anesthetized rat. Neuroscience 2005; 132: 1017-1026.
25. O'Connor LT Jr, Vaughan ED Jr, Felsen D. In vivo cystometric evaluation of progressive bladder outlet obstruction in rats. J Urol 1997; 158: 631-635.